Bridging commercial gaps to supercharge the UK life sciences sector

Blackstone's $6.3bn life sciences bid; ACC readouts for baxdrostat and lorundrostat ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

Share with friend    View in browser DECODED Pharmaceuticals March 31, 2026 SPOTLIGHT READ Navigating commercial gaps to supercharge the UK life sciences sector For the UK to fully harness its potential in the global life sciences market, commercial, funding and systemic challenges must be tackled. Client Showcase Gene therapy fill-finish: Critical factors for technical success and smooth CMO collaborations This paper provides an overview of the technical challenges and critical success factors involved in fill-finish – a crucial step in the manufacture and administration of gene therapies.   Download free whitepaper LATEST NEWS IN YOUR INDUSTRY Blackstone closes largest ever private funding investment round at $6.3bn Blackstone says this is the largest private life sciences fund ever raised, which will fund innovation in pharma and medtech.   ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension At the 2026 ACC, researchers presented a meta-analysis of three trials (1,264 patients) assessing baxdrostat's blood pressure and safety effects in uncontrolled hypertension.   ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk At the 2026 ACC in New Orleans, Brazilian investigators presented a meta-analysis of three trials (1,060 patients) evaluating lorundrostat's blood pressure-lowering effects and safety in uncontrolled hypertension.   2025 dominated in ALS research ALS remains a devastating neurodegenerative condition with limited treatments, but increasing clinical trial activity worldwide reflects growing scientific confidence that new therapeutic strategies may begin to slow disease progression.   Ayahuasca-derived DMT study shows positive effects on depression therapy in trials A clinical study suggests ayahuasca-derived DMT may offer an alternative to traditional antidepressants. The State of the Biopharmaceutical Industry 2026 GlobalData is conducting a short survey to understand how industry leaders view the evolving pharmaceutical landscape in 2026. As a respected professional in this field, your input will help shape GlobalData's report. Take the survey JP Morgan Healthcare Conference 2026: Post-Congress Report GlobalData's analyst and journalist teams have published a post-congress JPM 2026 report, distilling the most important announcements, deal activity, and strategic themes from the conference. Access the report Expand your subscription to other sectors   Subscribe to our other newsletters here. Was this email forwarded to you? Sign up here. Prefer a podcast? Instant Insights ranks in the top 10% of podcasts globally - follow us on Spotify, Apple, YouTube, and Amazon Music.   What keeps your CEO up at night? Generative AI, ESG, and disruptive technologies.  What is thematic intelligence and why do business executives need it?   Predict the future Find business opportunities based on 150 million+ signals showing what your customers and competitors will do in the next 5 years. GlobalData  At GlobalData we have a proven track record in helping thousands of companies, government organizations, and industry professionals benefit from faster, more informed decisions. You can update your communication preferences to make sure you receive the right information for you.  GlobalData, John Carpenter House | Registered in England No. 03925319, John Carpenter Street, London, EC4Y 0AN, United Kingdom   Unsubscribe  |   Manage Preferences London